@article{10.37349/eemd.2024.00006,
abstract = {Aim: Epigenetic alterations have been reported in patients with pituitary tumors and those on antipsychotic drugs, which are also responsible for hyperprolactinemia. This suggests a possible role of epigenetics in the etiopathology of hyperprolactinemia. Methods: The study recruited 83 hyperprolactinemia cases with prolactin > 100 ng/mL and 65 controls. Global DNA methylation status was studied by MethylFlash Methylated DNA Quantification Kit and genome-wide methylation analysis (GWMA) by Infinium Methylation EPIC BeadChip 850K array. Results: Hyperprolactinemia cases showed significant global DNA hypermethylation compared to controls. Around 66.67% of hypomethylated and 12.9% of hypermethylated cases were on antipsychotics. Gene enrichment analysis of 5-cytosine-phosphate-guanine-3 (CpG) site-associated genes demonstrated significantly enriched major histocompatibility complex (MHC)-related protein classes and cellular components. Conclusion: The study suggested the role of epigenetics in the etiopathology of hyperprolactinemia.},
author = {Kalsi, Amanpreet Kaur and Halder, Ashutosh and Jain, Manish and Sharma, Jai Bhagwan},
doi = {10.37349/eemd.2024.00006},
journal = {Exploration of Endocrine and Metabolic Diseases},
pages = {39--55},
title = {{Epigenetics in etiopathology of hyperprolactinemia}},
url = {https://www.explorationpub.com/Journals/eemd/Article/10146},
volume = {1},
year = {2024},
number = {2}
}